Reading the AI hype cycle for healthcare

Healthcare AI claims usually arrive before the evaluation surface is clear. A demo may summarize a chart, draft a note, identify a work queue, or predict a risk score, but the hospital still has to ask what the system changes inside a real workflow.

The durable question is not whether the output looks fluent. It is whether the system can be evaluated under clinical, security, privacy, operational, and procurement constraints. The more regulated the setting, the less useful it is to treat model quality as the only axis.

A practical hype filter starts with the task. Systems that help retrieve, summarize, extract, route, or draft information can often be assessed with existing human review patterns. Systems that imply diagnosis, triage, treatment direction, or autonomous action require a different level of clinical, legal, and safety review.

The second filter is data boundary. A credible vendor can describe what data the system needs, where that data moves, how long it is retained, which humans or services can access it, and how the hospital can audit that path. If the data path is vague, the product is not ready for serious healthcare evaluation.

The third filter is accountability. The hospital should be able to say who reviews the output, what happens when the system is wrong, how disagreement is handled, and how the workflow degrades if the tool is unavailable. AI that improves a demo but blurs ownership is not mature clinical infrastructure.

The fourth filter is measurement. Healthcare teams need to know what will be measured before a pilot starts: turnaround time, documentation quality, queue reduction, missed handoffs, reviewer burden, false positives, false negatives, or another operational outcome. Without that frame, every result is too easy to narrate after the fact.

The fifth filter is maturity. Some capabilities are ready for bounded workflow review today. Some are plausible but still require local validation, integration work, and governance design. Some are mostly language around a future product. The CIO or CMIO does not need to reject the category; they need to slow the conversation until each claim has an evaluation path.

The useful posture is neither enthusiasm nor dismissal. It is disciplined curiosity: name the workflow, name the data path, name the accountable reviewer, name the failure mode, and name the evidence that would change the decision.